Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069582 | 0.83 | NPC1 (0.53) | MEN1KMT2AALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL17667166 | 0.82 | ALDH1A1 (0.55) | MEN1KMT2AALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL17667165 | 0.82 | ALDH1A1 (0.55) | MEN1KMT2AALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL12256482 | 0.78 | MEN1 (0.40) | MEN1KMT2ALMNAALDH1A1NPSR1 | |
| SCHEMBL8826133 | 0.77 | MEN1 (0.54) | MEN1KMT2ATDP1LMNAALDH1A1 | |
| SCHEMBL8496217 | 0.77 | MEN1 (0.54) | MEN1KMT2ATDP1LMNAALDH1A1 | |
| SCHEMBL8496214 | 0.77 | MEN1 (0.54) | MEN1KMT2ATDP1LMNAALDH1A1 | |
| SCHEMBL8496219 | 0.77 | MEN1 (0.54) | MEN1KMT2ATDP1LMNAALDH1A1 | |
| SCHEMBL8826139 | 0.77 | MEN1 (0.54) | MEN1KMT2ATDP1LMNAALDH1A1 | |
| SCHEMBL6070017 | 0.76 | ALOX5 (0.50) | MEN1KMT2ATDP1SUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056947-B2 | For inhibiting (cysteine) proteases/caspases; for treatment of viral infections, stroke, neurodegenerative disease, and inflammatory diseases | GEORGIA TECH RESEARCH CORP. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20040048327-A1 | Aza-peptide epoxides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-03-11 | — | — | US | disclosed |
| WO-2004005270-A1 | AZA-PEPTIDE EPOXIDES | GEORGIA TECH RESEARCH CORPORATION (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048327-A1 | Aza-peptide epoxides | ANPEP, ENPEP, TMPRSS15 | MEN1 3405/4885KMT2A 2281/4885TDP1 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.